Russell Investments Group Ltd. decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 24.2% during the 3rd quarter, Holdings Channel reports. The firm owned 125,599 shares of the medical research company’s stock after selling 39,990 shares during the period. Russell Investments Group Ltd.’s holdings in Natera were worth $51,913,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Natera in the second quarter valued at $2,962,770,000. Bank of America Corp DE acquired a new position in Natera during the second quarter worth $199,960,000. Legal & General Group Plc acquired a new position in Natera during the second quarter worth $150,143,000. Bank of New York Mellon Corp acquired a new position in Natera during the second quarter worth $149,278,000. Finally, Avala Global LP bought a new stake in Natera during the second quarter worth $124,867,000. Institutional investors own 99.90% of the company’s stock.
Insiders Place Their Bets
In other news, insider John Fesko sold 302 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $400.01, for a total value of $120,803.02. Following the transaction, the insider directly owned 195,276 shares of the company’s stock, valued at $78,112,352.76. This represents a 0.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,801 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the completion of the transaction, the chief executive officer directly owned 87,431 shares in the company, valued at $36,004,085.80. The trade was a 4.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 47,056 shares of company stock worth $17,760,989. Company insiders own 5.05% of the company’s stock.
Wall Street Analyst Weigh In
NTRA has been the subject of a number of recent analyst reports. Citigroup increased their price target on shares of Natera from $365.00 to $480.00 and gave the company a “buy” rating in a research note on Tuesday, October 6th. Barclays boosted their price objective on shares of Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Rothschild & Co Redburn assumed coverage on shares of Natera in a research note on Tuesday, September 8th. They set a “buy” rating and a $385.00 price objective on the stock. TD Cowen upped their target price on shares of Natera from $340.00 to $480.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Finally, Robert W. Baird cut their target price on shares of Natera from $458.00 to $403.00 and set an “outperform” rating for the company in a research note on Monday, November 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus target price of $394.31.
Get Our Latest Research Report on NTRA
Natera Stock Performance
Shares of NASDAQ NTRA opened at $319.09 on Monday. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The stock has a 50 day moving average of $379.70 and a 200-day moving average of $271.61. The company has a market capitalization of $46.27 billion, a P/E ratio of -279.90 and a beta of 1.55.
Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. The business had revenue of $793.98 million during the quarter, compared to the consensus estimate of $707.54 million. During the same quarter last year, the company posted ($0.64) EPS. The firm’s revenue was up 34.1% on a year-over-year basis. Analysts predict that Natera, Inc. will post -1.25 EPS for the current fiscal year.
Natera Company Profile
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
Read More
- Five stocks we like better than Natera
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
